{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T23:21:52Z","timestamp":1787440912795,"version":"build-2736575974"},"reference-count":165,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006013","name":"United Arab Emirates University","doi-asserted-by":"publisher","award":["12M158"],"award-info":[{"award-number":["12M158"]}],"id":[{"id":"10.13039\/501100006013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.biopha.2026.119614","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T17:30:37Z","timestamp":1780939837000},"page":"119614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Repurposing antidiabetics for Alzheimer\u2019s disease and related neurodegenerative disorders: Translational challenges and role of nanoparticle-mediated CNS targeting"],"prefix":"10.1016","volume":"200","author":[{"given":"Lilian","family":"Alnsour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Al-Samydai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem","family":"Sadek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2789-8514","authenticated-orcid":false,"given":"Amal","family":"Akour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.biopha.2026.119614_bib1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11892-016-0775-x","article-title":"Diabetes and cognitive impairment","volume":"16","author":"Zilliox","year":"2016","journal-title":"Curr. Diab Rep."},{"issue":"11","key":"10.1016\/j.biopha.2026.119614_bib2","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/alz.12482","article-title":"The impact of diabetes on cognitive impairment and its progression to dementia","volume":"17","author":"Dove","year":"2021","journal-title":"Alzheimers Dement."},{"issue":"1","key":"10.1016\/j.biopha.2026.119614_bib3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrn2294","article-title":"Glucose neurotoxicity","volume":"9","author":"Tomlinson","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"issue":"9","key":"10.1016\/j.biopha.2026.119614_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024325","article-title":"Cognitive and emotional alterations are related to hippocampal inflammation in a mouse model of metabolic syndrome","volume":"6","author":"Dinel","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.biopha.2026.119614_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.pbb.2008.12.012","article-title":"Suppression of NF-\u03ba\u03b2 signaling pathway by tocotrienol can prevent diabetes associated cognitive deficits","volume":"92","author":"Kuhad","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"1","key":"10.1016\/j.biopha.2026.119614_bib6","doi-asserted-by":"crossref","first-page":"T31","DOI":"10.1530\/JOE-13-0221","article-title":"Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases","volume":"221","author":"H\u00f6lscher","year":"2014","journal-title":"J. Endocrinol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119614_bib7","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s13098-025-01930-2","article-title":"A systematic review on type 3 diabetes: bridging the gap between metabolic dysfunction and Alzheimer\u2019s disease","volume":"17","author":"Atabi","year":"2025","journal-title":"Diabetol. Metab. Syndr."},{"issue":"8","key":"10.1016\/j.biopha.2026.119614_bib8","doi-asserted-by":"crossref","DOI":"10.18103\/mra.v13i8.6866","article-title":"Neuroinflammation and cognitive health in type 2 diabetes","volume":"13","author":"Choudhary","year":"2025","journal-title":"Med. Res. Arch."},{"key":"10.1016\/j.biopha.2026.119614_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2025.1614962","article-title":"Biological determinants of blood-based biomarker levels in Alzheimer\u2019s disease: role of nutrition, inflammation, and metabolic factors","volume":"17","author":"Inamdar","year":"2025","journal-title":"Front. Aging Neurosci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119614_bib10","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3390\/cells9030740","article-title":"Insulin resistance promotes Parkinson\u2019s disease through aberrant expression of \u03b1-synuclein, mitochondrial dysfunction, and deregulation of the polo-like kinase 2 signaling","volume":"9","author":"Hong","year":"2020","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.biopha.2026.119614_bib11","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1556\/2060.103.2016.3.7","article-title":"Intranasal insulin treatment improves memory and learning in a rat amyloid-beta model of Alzheimer\u2019s disease","volume":"103","author":"Farzampour","year":"2016","journal-title":"Physiol. Int."},{"issue":"6","key":"10.1016\/j.biopha.2026.119614_bib12","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuropharm.2011.01.033","article-title":"Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer\u2019s-like changes","volume":"60","author":"Gupta","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2026.119614_bib13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.bbi.2017.12.009","article-title":"Metformin treatment prevents amyloid plaque deposition and memory impairment in APP\/PS1 mice","volume":"69","author":"Ou","year":"2018","journal-title":"Brain Behav. Immun."},{"issue":"5","key":"10.1016\/j.biopha.2026.119614_bib14","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s11357-011-9303-8","article-title":"Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer\u2019s disease by exendin-4","volume":"34","author":"Chen","year":"2012","journal-title":"AGE"},{"issue":"8","key":"10.1016\/j.biopha.2026.119614_bib15","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.1007\/s12035-016-0125-7","article-title":"Linagliptin, a dipeptidyl peptidase-4 inhibitor, mitigates cognitive deficits and pathology in the 3xTg-AD mouse model of Alzheimer\u2019s disease","volume":"54","author":"Kosaraju","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.biopha.2026.119614_bib16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.taap.2017.08.005","article-title":"SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats","volume":"333","author":"Sa-nguanmoo","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119614_bib17","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.3390\/ijms23126542","article-title":"The effectiveness of antidiabetic drugs in treating dementia: a peek into pharmacological and pharmacokinetic properties","volume":"23","author":"Ogura","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119614_bib18","doi-asserted-by":"crossref","unstructured":"Senanayake D., Yapa P., Dabare S., Munaweera I. Precision targeting of the CNS: recent progress in brain-directed nanodrug delivery [Internet]. 2025. doi:10.1039\/D5RA03578C.","DOI":"10.1039\/D5RA03578C"},{"issue":"1","key":"10.1016\/j.biopha.2026.119614_bib19","doi-asserted-by":"crossref","first-page":"a020412","DOI":"10.1101\/cshperspect.a020412","article-title":"The blood\u2013brain barrier","volume":"7","author":"Daneman","year":"2015","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119614_bib20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrn1824","article-title":"Astrocyte\u2013endothelial interactions at the blood\u2013brain barrier","volume":"7","author":"Abbott","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"issue":"5","key":"10.1016\/j.biopha.2026.119614_bib21","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.cell.2015.10.067","article-title":"Establishment and dysfunction of the blood-brain barrier","volume":"163","author":"Zhao","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.biopha.2026.119614_bib22","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3390\/pharmaceutics15051357","article-title":"Permeability of metformin across an in vitro blood-brain barrier model during normoxia and oxygen-glucose deprivation conditions: role of organic cation transporters (Octs)","volume":"15","author":"Sharma","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.biopha.2026.119614_bib23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3390\/ph18040486","article-title":"Overview of metformin and neurodegeneration: a comprehensive review","volume":"18","author":"Kruczkowska","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biopha.2026.119614_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114187","article-title":"Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer\u2019s and Parkinson\u2019s disease therapeutics","volume":"180","author":"Salameh","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119614_bib25","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40120-025-00724-y","article-title":"Are glucagon-like peptide-1 (GLP-1) receptor agonists central nervous system (CNS) penetrant: a narrative review","volume":"14","author":"West","year":"2025","journal-title":"Neurol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119614_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-49870-z","article-title":"Use of dipeptidyl peptidase-4 inhibitors was associated with a lower risk of Parkinson\u2019s disease in diabetic patients","volume":"13","author":"Lin","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119614_bib27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1556-276X-8-102","article-title":"Liposome: classification, preparation, and applications","volume":"8","author":"Akbarzadeh","year":"2013","journal-title":"Nanoscale Res. Lett."},{"issue":"2","key":"10.1016\/j.biopha.2026.119614_bib28","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3390\/encyclopedia2020063","article-title":"Solid lipid nanoparticles","volume":"2","author":"Nguyen","year":"2022","journal-title":"Encyclopedia"},{"issue":"3","key":"10.1016\/j.biopha.2026.119614_bib29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.15171\/apb.2015.043","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application","volume":"5","author":"Naseri","year":"2015","journal-title":"Adv. Pharm. Bull."},{"issue":"9","key":"10.1016\/j.biopha.2026.119614_bib30","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jsps.2021.07.015","article-title":"Nanostructured lipid carriers (NLCs) as drug delivery platform: advances in formulation and delivery strategies","volume":"29","author":"Elmowafy","year":"2021","journal-title":"Saudi Pharm. J."},{"issue":"2","key":"10.1016\/j.biopha.2026.119614_bib31","doi-asserted-by":"crossref","first-page":"150","DOI":"10.34172\/apb.2020.021","article-title":"Nanostructured lipid carriers: a groundbreaking approach for transdermal drug delivery","volume":"10","author":"Chauhan","year":"2020","journal-title":"Adv. Pharm. Bull."},{"issue":"3","key":"10.1016\/j.biopha.2026.119614_bib32","doi-asserted-by":"crossref","first-page":"446","DOI":"10.34172\/apb.2023.056","article-title":"An overview of nanostructured lipid carriers and its application in drug delivery through different routes","volume":"13","author":"Khan","year":"2023","journal-title":"Adv. Pharm. Bull."},{"issue":"4","key":"10.1016\/j.biopha.2026.119614_bib33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2174\/0113894501339455241101065040","article-title":"Unraveling neurological drug delivery: polymeric nanocarriers for enhanced blood-brain barrier penetration","volume":"26","author":"Inamdar","year":"2025","journal-title":"Curr. Drug. Targets"},{"issue":"1","key":"10.1016\/j.biopha.2026.119614_bib34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12943-025-02410-x","article-title":"PEGylated PLGA nanoparticles: unlocking advanced strategies for cancer therapy","volume":"24","author":"Kesharwani","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2026.119614_bib35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.trac.2015.06.014","article-title":"PLGA-based nanoparticles: a new paradigm in biomedical applications","volume":"80","author":"Sharma","year":"2016","journal-title":"TrAC. Trends Anal. Chem."},{"key":"10.1016\/j.biopha.2026.119614_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2020.110920","article-title":"Novel amphiphilic chitosan micelles as carriers for hydrophobic anticancer drugs","volume":"112","author":"Almeida","year":"2020","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.biopha.2026.119614_bib37","article-title":"Chitosan nanoparticles: green synthesis, biological activities, and sustainable frontiers in targeted drug delivery and cancer nanomedicine \u2013 a comprehensive review","volume":"35","author":"El-Saadony","year":"2025","journal-title":"Mater. Today Bio"},{"issue":"2","key":"10.1016\/j.biopha.2026.119614_bib38","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3390\/pharmaceutics15020398","article-title":"Dendrimers as modifiers of inorganic nanoparticles for therapeutic delivery in cancer","volume":"15","author":"Zenze","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119614_bib39","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8844030","article-title":"Dendrimers: a new race of pharmaceutical nanocarriers","volume":"2021","author":"Mittal","year":"2021","journal-title":"Biomed. Res. Int."},{"issue":"8","key":"10.1016\/j.biopha.2026.119614_bib40","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.3390\/pharmaceutics14081636","article-title":"Progress in polymeric micelles for drug delivery applications","volume":"14","author":"Kotta","year":"2022","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.biopha.2026.119614_bib41","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1007\/s12274-018-2152-3","article-title":"Strategies to improve micelle stability for drug delivery","volume":"11","author":"Lu","year":"2018","journal-title":"Nano Res."},{"issue":"10","key":"10.1016\/j.biopha.2026.119614_bib42","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3390\/pharmaceutics16101332","article-title":"Review of gold nanoparticles: synthesis, properties, shapes, cellular uptake, targeting, release mechanisms and applications in drug delivery and therapy","volume":"16","author":"Georgeous","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119614_bib43","article-title":"Current trends in silica based drug delivery systems","volume":"12","author":"Khoz","year":"2024","journal-title":"Eur. J. Med. Chem. Rep."},{"issue":"11","key":"10.1016\/j.biopha.2026.119614_bib44","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.clinthera.2023.08.017","article-title":"Use of silica nanoparticles for drug delivery in cardiovascular disease","volume":"45","author":"Kirla","year":"2023","journal-title":"Clin. Ther."},{"issue":"8","key":"10.1016\/j.biopha.2026.119614_bib45","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3390\/nano13081342","article-title":"Iron oxide@mesoporous silica core-shell nanoparticles as multimodal platforms for magnetic resonance imaging, magnetic hyperthermia, near-infrared light photothermia, and drug delivery","volume":"13","author":"Adam","year":"2023","journal-title":"Nanomaterials"},{"key":"10.1016\/j.biopha.2026.119614_bib46","doi-asserted-by":"crossref","unstructured":"Zhang Z., He S., Jiang W., Lu J., Liu S., Xu W., et al. Uptake of Mesenchymal Stem Cell-Derived Exosomes in Mouse Brain through Intranasal Delivery. Current Drug Delivery. 22(8):1112\u20131124. doi:10.2174\/0115672018339798240904171503.","DOI":"10.2174\/0115672018339798240904171503"},{"issue":"1","key":"10.1016\/j.biopha.2026.119614_bib47","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12929-024-01055-0","article-title":"Exosomes: a review of biologic function, diagnostic and targeted therapy applications, and clinical trials","volume":"31","author":"Chen","year":"2024","journal-title":"J. Biomed. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2026.119614_bib48","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3390\/cells8040307","article-title":"Review of the Isolation, Characterization, Biological Function, and Multifarious Therapeutic Approaches of Exosomes","volume":"8","author":"Gurunathan","year":"2019","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.biopha.2026.119614_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13770-023-00610-4","article-title":"Engineering of cell derived-nanovesicle as an alternative to exosome therapy","volume":"21","author":"Jang","year":"2023","journal-title":"Tissue Eng. Regen. Med."},{"issue":"2","key":"10.1016\/j.biopha.2026.119614_bib50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/pharmaceutics10020057","article-title":"Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems","volume":"10","author":"Danaei","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119614_bib51","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","article-title":"Nanoparticle-mediated brain drug delivery: Overcoming blood\u2013brain barrier to treat neurodegenerative diseases","volume":"235","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119614_bib52","series-title":"Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles. Located at: world","article-title":"American chemical society","author":"Alexis","year":"2008"},{"issue":"4","key":"10.1016\/j.biopha.2026.119614_bib53","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3390\/pharmaceutics14040883","article-title":"Nanocarrier drug delivery systems: characterization, limitations, future perspectives and implementation of artificial intelligence","volume":"14","author":"Alshawwa","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119614_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115114","article-title":"Protein corona on brain targeted nanocarriers: challenges and prospects","volume":"202","author":"Jiang","year":"2023","journal-title":"Adv. Drug. Deliv. Rev."},{"issue":"7","key":"10.1016\/j.biopha.2026.119614_bib55","doi-asserted-by":"crossref","first-page":"7292","DOI":"10.1021\/acsnano.8b03500","article-title":"Evolution of nanoparticle protein corona across the blood\u2013brain barrier","volume":"12","author":"Cox","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.biopha.2026.119614_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2019.101665","article-title":"Targeting the transferrin receptor for brain drug delivery","volume":"181","author":"Johnsen","year":"2019","journal-title":"Progress. Neurobiol."},{"issue":"21","key":"10.1016\/j.biopha.2026.119614_bib57","doi-asserted-by":"crossref","first-page":"8662","DOI":"10.1073\/pnas.1307152110","article-title":"Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor","volume":"110","author":"Wiley","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"40","key":"10.1016\/j.biopha.2026.119614_bib58","doi-asserted-by":"crossref","first-page":"12486","DOI":"10.1073\/pnas.1517048112","article-title":"Increased brain uptake of targeted nanoparticles by adding an acid-cleavable linkage between transferrin and the nanoparticle core","volume":"112","author":"Clark","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.biopha.2026.119614_bib59","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s13346-022-01245-z","article-title":"Transferrin-modified chitosan nanoparticles for targeted nose-to-brain delivery of proteins","volume":"13","author":"Gabold","year":"2023","journal-title":"Drug. Deliv. Transl. Res."},{"issue":"22","key":"10.1016\/j.biopha.2026.119614_bib60","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1007\/s00018-005-5371-1","article-title":"Lactoferrin","volume":"62","author":"Suzuki","year":"2005","journal-title":"Cell. Mol. Life Sci."},{"issue":"12","key":"10.1016\/j.biopha.2026.119614_bib61","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1038\/jcbfm.2009.104","article-title":"Brain-targeting mechanisms of lactoferrin-modified DNA-loaded nanoparticles","volume":"29","author":"Huang","year":"2009","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.biopha.2026.119614_bib62","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3389\/fnins.2019.00521","article-title":"Role of the blood-brain barrier in central nervous system insulin resistance","volume":"13","author":"Rhea","year":"2019","journal-title":"Front. Neurosci."},{"issue":"S13","key":"10.1016\/j.biopha.2026.119614_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/alz.070972","article-title":"The role of the blood-brain barrier in brain insulin signaling","volume":"19","author":"Calon","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"issue":"3","key":"10.1016\/j.biopha.2026.119614_bib64","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1152\/physrev.00033.2007","article-title":"The low density lipoprotein receptor-related protein 1: Unique tissue-specific functions revealed by selective gene knockout studies","volume":"88","author":"Lillis","year":"2008","journal-title":"Physiol. Rev."},{"issue":"5","key":"10.1016\/j.biopha.2026.119614_bib65","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.nano.2011.05.004","article-title":"Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model","volume":"7","author":"Re","year":"2011","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.biopha.2026.119614_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13010038","article-title":"ApoE-targeting increases the transfer of solid lipid nanoparticles with donepezil cargo across a culture model of the blood\u2013brain barrier","volume":"13","author":"Topal","year":"2020","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.biopha.2026.119614_bib67","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.5599\/admet.2988","article-title":"Advancing through the blood-brain barrier: mechanisms, challenges and drug delivery strategies","volume":"13","author":"Vargas","year":"2025","journal-title":"ADMET DMPK"},{"key":"10.1016\/j.biopha.2026.119614_bib68","first-page":"640","article-title":"Modern methods for delivery of drugs across the blood\u2013brain barrier","volume":"64","author":"Chen","year":"2012"},{"issue":"33","key":"10.1016\/j.biopha.2026.119614_bib69","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1016\/j.biomaterials.2008.08.004","article-title":"TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs","volume":"29","author":"Rao","year":"2008","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.biopha.2026.119614_bib70","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1208\/s12248-008-9055-2","article-title":"CNS delivery via adsorptive transcytosis","volume":"10","author":"Herv\u00e9","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.biopha.2026.119614_bib71","first-page":"28","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016"},{"issue":"3","key":"10.1016\/j.biopha.2026.119614_bib72","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jconrel.2010.03.016","article-title":"Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting","volume":"145","author":"Li","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119614_bib73","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2147\/IJN.S439181","article-title":"Recent advances in intranasal administration for brain-targeting delivery: a comprehensive review of lipid-based nanoparticles and stimuli-responsive gel formulations","volume":"19","author":"Koo","year":"2024","journal-title":"IJN"},{"key":"10.1016\/j.biopha.2026.119614_bib74","first-page":"168","article-title":"Drug delivery through nose: a noninvasive technique for brain targeting [systematic review] [Internet]","author":"Thakur","year":"2019","journal-title":"J. Rep. Pharm. Sci."},{"key":"10.1016\/j.biopha.2026.119614_bib75","article-title":"Chitosan nanoparticles to enhance nasal absorption and brain targeting of sitagliptin to treat Alzheimer\u2019s disease","volume":"61","author":"Wilson","year":"2021","journal-title":"J. Drug. Deliv. Sci. Technol."},{"issue":"24","key":"10.1016\/j.biopha.2026.119614_bib76","doi-asserted-by":"crossref","first-page":"13258","DOI":"10.3390\/ijms222413258","article-title":"In vitro comparative study of solid lipid and PLGA nanoparticles designed to facilitate nose-to-brain delivery of insulin","volume":"22","author":"Akel","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119614_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/polym10030316","article-title":"Comparative study of ex vivo transmucosal permeation of pioglitazone nanoparticles for the treatment of Alzheimer\u2019s disease","volume":"10","author":"Silva-Abreu","year":"2018","journal-title":"Polymers"},{"issue":"1","key":"10.1016\/j.biopha.2026.119614_bib78","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-22844-z","article-title":"Evaluation of the neuroprotective potential of optimized intranasal polydopamine nanoparticles in a lipopolysaccharide-induced rat model for Alzheimer\u2019s disease management","volume":"15","author":"Ibrahim","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119614_bib79","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jconrel.2015.08.059","article-title":"Drug and gene delivery across the blood-brain barrier with focused ultrasound","volume":"219","author":"Timbie","year":"2015","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.biopha.2026.119614_bib80","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1073\/pnas.91.6.2076","article-title":"Convection-enhanced delivery of macromolecules in the brain","volume":"91","author":"Bobo","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.biopha.2026.119614_bib81","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm850","article-title":"Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease","volume":"9","author":"Gill","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2026.119614_bib82","article-title":"Intranasal administration of silibinin-loaded pullulan acetate nanocarriers: A pH-responsive approach for brain targeting in Alzheimer\u2019s disease","volume":"93","author":"Revdekar","year":"2024","journal-title":"J. Drug. Deliv. Sci. Technol."},{"key":"10.1016\/j.biopha.2026.119614_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119292","article-title":"Reactive oxygen species-responsive drug delivery systems for the treatment of neurodegenerative diseases","volume":"217","author":"Ballance","year":"2019","journal-title":"Biomaterials"},{"issue":"12","key":"10.1016\/j.biopha.2026.119614_bib84","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/j.biomaterials.2009.01.026","article-title":"Reduction-sensitive polymers and bioconjugates for biomedical applications","volume":"30","author":"Meng","year":"2009","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.biopha.2026.119614_bib85","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.bbrc.2015.08.030","article-title":"Magnetic iron oxide nanoparticles: recent trends in design and synthesis of magnetoresponsive nanosystems","author":"Tomb\u00e1cz","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.biopha.2026.119614_bib86","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1016\/j.apsb.2025.02.035","article-title":"Nose-to-brain delivery of targeted lipid nanoparticles as two-pronged \u03b2-amyloid nanoscavenger for Alzheimer\u2019s disease therapy","volume":"15","author":"Xu","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biopha.2026.119614_bib87","doi-asserted-by":"crossref","unstructured":"Yao H., Zhang A., Li D., Wu Y., Wang C.Z., Wan J.Y., et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis [Internet]. 2024. doi:10.1136\/bmj-2023-076410.","DOI":"10.1136\/bmj-2023-076410"},{"key":"10.1016\/j.biopha.2026.119614_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.171079","article-title":"Viktor Mutt lecture: peptides can cross the blood-brain barrier","volume":"169","author":"Banks","year":"2023","journal-title":"Peptides"},{"issue":"3","key":"10.1016\/j.biopha.2026.119614_bib89","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.ijo.0802206","article-title":"Entry of exendin-4 into brain is rapid but may be limited at high doses","volume":"27","author":"Kastin","year":"2003","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"issue":"1","key":"10.1016\/j.biopha.2026.119614_bib90","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41591-025-04106-7","article-title":"Liraglutide in mild to moderate Alzheimer\u2019s disease: a phase 2b clinical trial","volume":"32","author":"Edison","year":"2026","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119614_bib91","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","article-title":"evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer\u2019s disease","volume":"17","author":"Cummings","year":"2025","journal-title":"Alz Res. Ther."},{"key":"10.1016\/j.biopha.2026.119614_bib92","unstructured":"Novo Nordisk A.\/S.. A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer\u00b4s Disease (EVOKE Plus) [Clinical trial registration] [Internet]. clinicaltrials.gov; 2026 Mar [cited 2026 Jun 1]. Clinical trial registration no.: NCT04777409. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT04777409\u3009."},{"issue":"1","key":"10.1016\/j.biopha.2026.119614_bib93","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12967-024-04927-z","article-title":"Tirzepatide prevents neurodegeneration through multiple molecular pathways","volume":"22","author":"Fontanella","year":"2024","journal-title":"J. Transl. Med."},{"issue":"5","key":"10.1016\/j.biopha.2026.119614_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00712","article-title":"From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics","volume":"22","author":"Roy","year":"2025","journal-title":"Neurotherapeutics"},{"issue":"7_Supplement_1","key":"10.1016\/j.biopha.2026.119614_bib95","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1212\/WNL.0000000000211906","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists for Parkinson\u2019s disease: a systematic review and meta-analysis of randomized controlled trials (P11-5.012)","volume":"104","author":"Waseem","year":"2025","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.biopha.2026.119614_bib96","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.2337\/db14-0052","article-title":"Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors","volume":"63","author":"Omar","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2026.119614_bib97","unstructured":"Sulangi A.J., Lyons S.E., Abdou A.A., Patel H., Nagliya D., Joseph E., et al. Exploring the Therapeutic Potential of DPP4 Inhibitors in Alzheimer\u2019s Disease: Molecular Insight and Clinical Outcome. Cureus. 16(10):e72648. doi:10.7759\/cureus.72648 PubMed PMID: 39610591; PubMed Central PMCID: PMC11604213."},{"key":"10.1016\/j.biopha.2026.119614_bib98","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-49870-z","article-title":"Use of dipeptidyl peptidase-4 inhibitors was associated with a lower risk of Parkinson\u2019s disease in diabetic patients","volume":"13","author":"Lin","year":"2023","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2026.119614_bib99","first-page":"360","article-title":"Metformin improves memory via AMPK\/mTOR-dependent route in a rat model of Alzheimer\u2019s disease","volume":"27","author":"Ale Mahmoud Mehraban","year":"2024","journal-title":"Iran. J. Basic. Med. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119614_bib100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10522-018-9773-5","article-title":"Metformin as a geroprotector: experimental and clinical evidence","volume":"20","author":"Piskovatska","year":"2019","journal-title":"Biogerontology"},{"issue":"4","key":"10.1016\/j.biopha.2026.119614_bib101","first-page":"486","article-title":"Overview of metformin and neurodegeneration: a comprehensive review","volume":"18","author":"Kruczkowska","year":"2025","journal-title":"Pharm. (Basel)"},{"issue":"4","key":"10.1016\/j.biopha.2026.119614_bib102","doi-asserted-by":"crossref","first-page":"706","DOI":"10.14283\/jpad.2023.113","article-title":"Metformin in the prevention of Alzheimer\u2019s disease and Alzheimer\u2019s disease related dementias","volume":"10","author":"Tahmi","year":"2023","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"issue":"12","key":"10.1016\/j.biopha.2026.119614_bib103","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2012.189","article-title":"Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice","volume":"3","author":"Masciopinto","year":"2012","journal-title":"Cell. Death Dis."},{"issue":"34","key":"10.1016\/j.biopha.2026.119614_bib104","doi-asserted-by":"crossref","first-page":"7805","DOI":"10.1523\/JNEUROSCI.2038-05.2005","article-title":"The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice","volume":"25","author":"Sch\u00fctz","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2026.119614_bib105","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2010675","article-title":"Signaling mechanisms of selective PPAR\u03b3 modulators in Alzheimer\u2019s disease","volume":"2018","author":"Govindarajulu","year":"2018","journal-title":"PPAR Res."},{"issue":"5","key":"10.1016\/j.biopha.2026.119614_bib106","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/neup.12665","article-title":"Sodium\/glucose cotransporter 2 is expressed in choroid plexus epithelial cells and ependymal cells in human and mouse brains","volume":"40","author":"Chiba","year":"2020","journal-title":"Neuropathology"},{"issue":"9","key":"10.1016\/j.biopha.2026.119614_bib107","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00424-020-02441-x","article-title":"Glucose transporters in brain in health and disease","volume":"472","author":"Koepsell","year":"2020","journal-title":"Pflug. Arch. - Eur. J. Physiol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119614_bib108","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3390\/antiox10081166","article-title":"Emergence of SGLT2 inhibitors as powerful antioxidants in human diseases","volume":"10","author":"Tsai","year":"2021","journal-title":"Antioxid. (Basel)"},{"issue":"1","key":"10.1016\/j.biopha.2026.119614_bib109","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13195-020-00607-4","article-title":"Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer\u2019s disease and type 2 diabetes","volume":"12","author":"Hierro-Bujalance","year":"2020","journal-title":"Alz Res. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2026.119614_bib110","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.4103\/1673-5374.385865","article-title":"Empagliflozin reduces brain pathology in Alzheimer\u2019s disease and type 2 diabetes","volume":"19","author":"Hierro-Bujalance","year":"2024","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.biopha.2026.119614_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2021.105158","article-title":"Empagliflozin nanoparticles attenuates type2 diabetes induced cognitive impairment via oxidative stress and inflammatory pathway in high fructose diet induced hyperglycemic mice","volume":"150","author":"Khan","year":"2021","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.biopha.2026.119614_bib112","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cbi.2017.08.013","article-title":"Canagliflozin prevents scopolamine-induced memory impairment in rats: comparison with galantamine hydrobromide action","volume":"277","author":"Arafa","year":"2017","journal-title":"Chem. Biol. Interact."},{"issue":"6","key":"10.1016\/j.biopha.2026.119614_bib113","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1007\/s40120-025-00832-9","article-title":"SGLT-2 inhibitors in the prevention and progression of neurodegenerative diseases: a narrative review","volume":"14","author":"Kostrzewska","year":"2025","journal-title":"Neurol. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2026.119614_bib114","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/13872877251329474","article-title":"Neuroprotective effects of SGLT2 inhibitors empagliflozin and dapagliflozin on A\u03b21\u201342-induced neurotoxicity and neuroinflammation in cellular models of Alzheimer\u2019s disease","volume":"105","author":"Alami","year":"2025","journal-title":"J. Alzheimer\u2019S. Dis."},{"key":"10.1016\/j.biopha.2026.119614_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115755","article-title":"SGLT2 and DPP4 inhibitors improve Alzheimer\u2019s disease\u2013like pathology and cognitive function through distinct mechanisms in a T2D\u2013AD mouse model","volume":"168","author":"Sim","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.biopha.2026.119614_bib116","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3390\/biomedicines11041025","article-title":"The effect of the sodium\u2014glucose cotransporter inhibitor on cognition and metabolic parameters in a rat model of sporadic Alzheimer\u2019s disease","volume":"11","author":"Osmanovi\u0107 Barilar","year":"2023","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.biopha.2026.119614_bib117","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11481-024-10140-y","article-title":"Canagliflozin mitigated cognitive impairment in streptozotocin-induced sporadic Alzheimer\u2019s disease in mice: role of AMPK\/SIRT-1 signaling pathway in modulating neuroinflammation","volume":"19","author":"Khamies","year":"2024","journal-title":"J. Neuroimmune Pharmacol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119614_bib118","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.3390\/ph16111620","article-title":"Preclinical studies of canagliflozin, a sodium-glucose co-transporter 2 inhibitor, and donepezil combined therapy in Alzheimer\u2019s disease","volume":"16","author":"Stanciu","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"9","key":"10.1016\/j.biopha.2026.119614_bib119","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/jcbfm.2012.91","article-title":"Sulfonylurea receptor 1 in central nervous system injury: a focused review","volume":"32","author":"Simard","year":"2012","journal-title":"J. Cereb. Blood Flow. Metab."},{"issue":"10","key":"10.1016\/j.biopha.2026.119614_bib120","doi-asserted-by":"crossref","first-page":"6590","DOI":"10.1007\/s12035-022-02998-x","article-title":"Glibenclamide directly prevents neuroinflammation by targeting SUR1-TRPM4-mediated NLRP3 inflammasome activation in microglia","volume":"59","author":"He","year":"2022","journal-title":"Mol. Neurobiol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119614_bib121","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.psyneuen.2004.04.003","article-title":"Intranasal insulin improves memory in humans","volume":"29","author":"Benedict","year":"2004","journal-title":"Psychoneuroendocrinology"},{"issue":"6","key":"10.1016\/j.biopha.2026.119614_bib122","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1212\/01.WNL.0000265401.62434.36","article-title":"Intranasal insulin improves cognition and modulates \u03b2-amyloid in early AD","volume":"70","author":"Reger","year":"2008","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.biopha.2026.119614_bib123","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0301-0082(91)90015-S","article-title":"Insulin receptors in the central nervous system: Localization, signalling mechanisms and functional aspects","volume":"36","author":"Unger","year":"1991","journal-title":"Progress. Neurobiol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119614_bib124","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.npp.1301193","article-title":"Intranasal Insulin Improves Memory in Humans: Superiority of Insulin Aspart","volume":"32","author":"Benedict","year":"2007","journal-title":"Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119614_bib125","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3233\/JAD-2012-121294","article-title":"Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes","volume":"33","author":"Yang","year":"2013","journal-title":"J. Alzheimer\u2019s Dis."},{"issue":"7","key":"10.1016\/j.biopha.2026.119614_bib126","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/1753425920930074","article-title":"Effect of berberine on LPS-induced expression of NF-\u03baB\/MAPK signalling pathway and related inflammatory cytokines in porcine intestinal epithelial cells","volume":"26","author":"Zhu","year":"2020","journal-title":"Innate Immun."},{"key":"10.1016\/j.biopha.2026.119614_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.prmcm.2025.100689","article-title":"Targeting AMPK signaling: The therapeutic potential of berberine in diabetes and its complications","volume":"17","author":"Mbara","year":"2025","journal-title":"Pharmacol. Res. - Mod. Chin. Med."},{"key":"10.1016\/j.biopha.2026.119614_bib128","article-title":"Berberine reduces A\u03b242 deposition and tau hyperphosphorylation via ameliorating endoplasmic reticulum stress","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119614_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114550","article-title":"Berberine alleviates Alzheimer\u2019s disease by activating autophagy and inhibiting ferroptosis through the JNK-p38MAPK signaling pathway","volume":"155","author":"Sun","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2026.119614_bib130","doi-asserted-by":"crossref","unstructured":"Warsi S.Z.A., Parvez A., Noman A.A., Siddiqui S.A., Ahmed F., Rahman A., et al. Neuroprotective and Antioxidant Effects of Pseudoelephantopus spicatus. Central Nervous System Agents in Medicinal Chemistry. 25:1\u201316. doi:10.2174\/0118715249382386250831055558.","DOI":"10.2174\/0118715249382386250831055558"},{"key":"10.1016\/j.biopha.2026.119614_bib131","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.2147\/IJN.S171490","article-title":"PPAR\u03b3 agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer\u2019s disease: in vitro and in vivo studies","volume":"13","author":"Silva-Abreu","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2026.119614_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117861","article-title":"Metformin loaded phosphatidylserine nanoliposomes improve memory deficit and reduce neuroinflammation in streptozotocin-induced Alzheimer\u2019s disease model","volume":"255","author":"Saffari","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2026.119614_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106348","article-title":"Novel therapeutic mechanism of action of metformin and its nanoformulation in Alzheimer\u2019s disease and role of AKT\/ERK\/GSK pathway","volume":"181","author":"Kumar","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2026.119614_bib134","doi-asserted-by":"crossref","first-page":"10401","DOI":"10.2147\/IJN.S479670","article-title":"Exenatide-modified deferoxamine-based nanoparticles ameliorates neurological deficits in Parkinson\u2019s disease mice","volume":"19","author":"Huang","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2026.119614_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124218","article-title":"Brain-targeted Tet-1 peptide-PLGA nanoparticles for berberine delivery against STZ-induced Alzheimer\u2019s disease in a rat model: Alleviation of hippocampal synaptic dysfunction, Tau pathology, and amyloidogenesis","volume":"658","author":"Saleh","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119614_bib136","doi-asserted-by":"crossref","unstructured":"Sharma H., Chandra P. Quercetin-loaded Nanoliposomes as a Novel Neuroprotective Strategy for Alzheimer\u2019s Disease. Micro and Nanosystems. 17:1\u201312. doi:10.2174\/0118764029388830250808034502.","DOI":"10.2174\/0118764029388830250808034502"},{"key":"10.1016\/j.biopha.2026.119614_bib137","doi-asserted-by":"crossref","unstructured":"Sharma H., Chandra P. Development of ergosterol nanoliposome-based delivery system pertaining toxicity evaluation and therapeutic potential for Alzheimer\u2019s disease. CNS & Neurological Disorders - Drug Targets. 25(1):56\u201366. doi:10.2174\/0118715273388820250724174247.","DOI":"10.2174\/0118715273388820250724174247"},{"issue":"4","key":"10.1016\/j.biopha.2026.119614_bib138","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40005-019-00439-x","article-title":"Biocompatibility, biodegradation and biomedical applications of poly(lactic acid)\/poly(lactic-co-glycolic acid) micro and nanoparticles","volume":"49","author":"Elmowafy","year":"2019","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.biopha.2026.119614_bib139","article-title":"Nanoparticle-induced complement activation: implications for cancer nanomedicine","volume":"11","author":"La-Beck","year":"2020","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119614_bib140","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","article-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"12","key":"10.1016\/j.biopha.2026.119614_bib141","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.3390\/mi13122091","article-title":"Hemolytic activity of nanoparticles as a marker of their hemocompatibility","volume":"13","author":"Yedgar","year":"2022","journal-title":"Micromachines"},{"issue":"2","key":"10.1016\/j.biopha.2026.119614_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2022.152317","article-title":"Nanoparticle-induced immune response: Health risk versus treatment opportunity?","volume":"228","author":"Pondman","year":"2023","journal-title":"Immunobiology"},{"key":"10.1016\/j.biopha.2026.119614_bib143","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.2147\/IJN.S443168","article-title":"Long-term accumulation, biological effects and toxicity of BSA-coated gold nanoparticles in the mouse liver, spleen, and kidneys","volume":"19","author":"Jakic","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2026.119614_bib144","article-title":"Iron oxide nanoparticles in biological systems: antibacterial and toxicology perspective","author":"Ezealigo","year":"2021","journal-title":"J. Colloid Interface Sci."},{"issue":"4","key":"10.1016\/j.biopha.2026.119614_bib145","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1007\/s12011-021-02774-3","article-title":"Silica nanoparticles induce hepatotoxicity by triggering oxidative damage, apoptosis, and Bax-Bcl2 signaling pathway","volume":"200","author":"Aouey","year":"2022","journal-title":"Biol. Trace Elem. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119614_bib146","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s11671-025-04215-9","article-title":"Systematic review of peptide nanoparticles for improved diabetes outcomes: insights and opportunities","volume":"20","author":"Dangana","year":"2025","journal-title":"Discov. Nano"},{"key":"10.1016\/j.biopha.2026.119614_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114708","article-title":"Nanoparticle biodistribution coefficients: a quantitative approach for understanding the tissue distribution of nanoparticles","volume":"194","author":"Kumar","year":"2023","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.biopha.2026.119614_bib148","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2019.10.006","article-title":"Chitosan coating of zein-carboxymethylated short-chain amylose nanocomposites improves oral bioavailability of insulin in vitro and in vivo","volume":"313","author":"Ji","year":"2019","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.biopha.2026.119614_bib149","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41565-018-0246-4","article-title":"Minimum information reporting in bio\u2013nano experimental literature","volume":"13","author":"Faria","year":"2018","journal-title":"Nat. Nanotech"},{"issue":"0 0","key":"10.1016\/j.biopha.2026.119614_bib150","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jconrel.2015.08.056","article-title":"Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: challenges, considerations and strategy","volume":"220","author":"Dobrovolskaia","year":"2015","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.biopha.2026.119614_bib151","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nnano.2007.223","article-title":"Immunological properties of engineered nanomaterials","volume":"2","author":"Dobrovolskaia","year":"2007","journal-title":"Nat. Nanotech"},{"key":"10.1016\/j.biopha.2026.119614_bib152","series-title":"Nanotechnology Guidance Documents [Internet]","author":"Office of the Commissioner","year":"2024"},{"key":"10.1016\/j.biopha.2026.119614_bib153","series-title":"Drug Products, Including Biological Products, that Contain Nanomaterials - Guidance for Industry [Internet]","author":"Center for Drug Evaluation and Research","year":"2022"},{"key":"10.1016\/j.biopha.2026.119614_bib154","series-title":"Reflection Paper on Nanotechnology-Based Medicinal Products for Human Use [Internet]","author":"European Medicines Agency","year":"2006"},{"key":"10.1016\/j.biopha.2026.119614_bib155","series-title":"Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation [Internet]","author":"Center for Drug Evaluation and Research","year":"2021"},{"key":"10.1016\/j.biopha.2026.119614_bib156","article-title":"Current regulatory landscape of nanomaterials and nanomedicines: a global perspective","volume":"80","author":"Ali","year":"2023","journal-title":"J. Drug. Deliv. Sci. Technol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119614_bib157","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s13346-021-01024-2","article-title":"Current hurdles to the translation of nanomedicines from bench to the clinic","volume":"12","author":"\u0110or\u0111evi\u0107","year":"2022","journal-title":"Drug. Deliv. Transl. Res."},{"key":"10.1016\/j.biopha.2026.119614_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.nwnano.2025.100127","article-title":"Nanomaterials for biomedical applications: addressing regulatory hurdles and strategic solutions","volume":"11","author":"Gujjar","year":"2025","journal-title":"Nano Trends"},{"issue":"8","key":"10.1016\/j.biopha.2026.119614_bib159","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41582-018-0032-9","article-title":"Sex differences in Alzheimer disease \u2014 the gateway to precision medicine","volume":"14","author":"Ferretti","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119614_bib160","doi-asserted-by":"crossref","DOI":"10.1002\/anbr.202200089","article-title":"Sex-based differences in the biodistribution of nanoparticles and their effect on hormonal, immune, and metabolic function","volume":"2","author":"Poley","year":"2022","journal-title":"Adv. NanoBiomed Res."},{"key":"10.1016\/j.biopha.2026.119614_bib161","first-page":"456","article-title":"Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines","volume":"172","author":"Dobrovolskaia","year":"2013"},{"issue":"9","key":"10.1016\/j.biopha.2026.119614_bib162","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1007\/s00204-021-03115-y","article-title":"Differences in P-glycoprotein activity in human and rodent blood\u2013brain barrier assessed by mechanistic modelling","volume":"95","author":"Verscheijden","year":"2021","journal-title":"Arch. Toxicol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119614_bib163","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1124\/jpet.120.000267","article-title":"Transport properties of statins by organic anion transporting polypeptide 1A2 and regulation by transforming growth factor-\u03b2 signaling in human endothelial cells","volume":"376","author":"Ronaldson","year":"2021","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2026.119614_bib164","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv. Drug. Deliv. Rev."},{"issue":"5","key":"10.1016\/j.biopha.2026.119614_bib165","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrd3978","article-title":"Extracellular vesicles: biology and emerging therapeutic opportunities","volume":"12","author":"EL Andaloussi","year":"2013","journal-title":"Nat. Rev. Drug. Discov."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226006505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226006505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T22:40:36Z","timestamp":1787438436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226006505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":165,"alternative-id":["S0753332226006505"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119614","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing antidiabetics for Alzheimer\u2019s disease and related neurodegenerative disorders: Translational challenges and role of nanoparticle-mediated CNS targeting","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119614","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119614"}}